Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2.
作者信息
Jiang Shibo, Zhang Xiujuan, Du Lanying
机构信息
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
Key Laboratory of Medical Molecular Virology (MOE/MOH/CAM), School of Basic Medical Sciences, Fudan University, Shanghai, China.
出版信息
Expert Opin Ther Targets. 2021 Jun;25(6):415-421. doi: 10.1080/14728222.2020.1820482. Epub 2020 Sep 17.
Abstract
摘要
相似文献
1
Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2.靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白的治疗性抗体和融合抑制剂。
Expert Opin Ther Targets. 2021 Jun;25(6):415-421. doi: 10.1080/14728222.2020.1820482. Epub 2020 Sep 17.
2
Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike.刺突依赖性 SARS-CoV-2 融合抑制剂及靶向刺突 S2 亚单位的小分子的研究进展。
Viruses. 2024 Apr 30;16(5):712. doi: 10.3390/v16050712.
3
N-terminal domain of SARS CoV-2 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白N端结构域突变与接种疫苗个体中和抗体有效性降低相关。
J Med Virol. 2021 Oct;93(10):5726-5728. doi: 10.1002/jmv.27181. Epub 2021 Jul 14.
4
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
5
Exploring SARS-CoV-2 Spikes Glycoproteins for Designing Potential Antiviral Targets.探索 SARS-CoV-2 刺突糖蛋白以设计潜在的抗病毒靶点。
Viral Immunol. 2021 Oct;34(8):510-521. doi: 10.1089/vim.2021.0023. Epub 2021 May 20.
6
Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.针对 SARS-CoV-2 细胞进入机制的靶向治疗策略：体外和体内研究的系统评价。
J Cell Physiol. 2021 Apr;236(4):2364-2392. doi: 10.1002/jcp.30032. Epub 2020 Sep 9.
7
The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.SARS-CoV-2 刺突糖蛋白的生物发生：宿主定向抗病毒治疗的多个靶点。
Biochem Biophys Res Commun. 2021 Jan 29;538:80-87. doi: 10.1016/j.bbrc.2020.10.080. Epub 2020 Nov 28.
8
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
9
Structure-based development of human antibody cocktails against SARS-CoV-2.基于结构的抗SARS-CoV-2人源抗体鸡尾酒疗法的开发。
Cell Res. 2021 Jan;31(1):101-103. doi: 10.1038/s41422-020-00446-w. Epub 2020 Dec 1.
10
Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.基于新冠病毒刺突蛋白的疫苗可能对粒细胞-巨噬细胞集落刺激因子（GM-CSF）的产生具有抑制作用。
Mol Med. 2021 May 22;27(1):49. doi: 10.1186/s10020-021-00313-3.
引用本文的文献
1
The Use of Heterologous Antigens for Biopanning Enables the Selection of Broadly Neutralizing Nanobodies Against SARS-CoV-2.使用异源抗原进行生物淘选可筛选出针对严重急性呼吸综合征冠状病毒2的广谱中和纳米抗体。
Antibodies (Basel). 2025 Mar 7;14(1):23. doi: 10.3390/antib14010023.
2
Cold-adapted live attenuated MERS-CoV vaccine strain remains attenuated in mice after multiple passages in Vero cells at 37 °C.在 37°C 的条件下，在 Vero 细胞中多次传代后，适应寒冷的减毒活中东呼吸综合征冠状病毒疫苗株在小鼠中仍保持减毒状态。
Arch Microbiol. 2024 Sep 6;206(10):393. doi: 10.1007/s00203-024-04120-2.
3
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses.针对 SARS-CoV-2 和其他致病性人冠状病毒的治疗性纳米抗体。
J Nanobiotechnology. 2024 May 31;22(1):304. doi: 10.1186/s12951-024-02573-7.
4
Antigen-Heterologous Vaccination Regimen Triggers Alternate Antibody Targeting in SARS-CoV-2-DNA-Vaccinated Mice.抗原异源疫苗接种方案在接种SARS-CoV-2-DNA疫苗的小鼠中引发交替抗体靶向作用。
Vaccines (Basel). 2024 Feb 20;12(3):218. doi: 10.3390/vaccines12030218.
5
Structural and pKa Estimation of the Amphipathic HR1 in SARS-CoV-2: Insights from Constant pH MD, Linear vs. Nonlinear Normal Mode Analysis.SARS-CoV-2 中两亲性 HR1 的结构和 pKa 估算：恒 pHMD、线性与非线性正则模态分析的启示。
Int J Mol Sci. 2023 Nov 10;24(22):16190. doi: 10.3390/ijms242216190.
6
Molecular interactions between perlecan LG3 and the SARS-CoV-2 spike protein receptor binding domain.LG3 型蛋白聚糖与 SARS-CoV-2 刺突蛋白受体结合域的分子相互作用。
Protein Sci. 2024 Jan;33(1):e4843. doi: 10.1002/pro.4843.
7
A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants.一种新型双特异性抗体双靶向方法，可增强对快速进化的 SARS-CoV-2 变体的中和作用。
Front Immunol. 2023 Sep 26;14:1271508. doi: 10.3389/fimmu.2023.1271508. eCollection 2023.
8
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking.靶向 SARS-CoV-2 刺突糖蛋白四元结构域的抗体通过构象锁定防止病毒受体结合。
Immunity. 2023 Oct 10;56(10):2442-2455.e8. doi: 10.1016/j.immuni.2023.09.003. Epub 2023 Sep 29.
9
SARS-CoV-2 Spike Protein Is Capable of Inducing Cell-Cell Fusions Independent from Its Receptor ACE2 and This Activity Can Be Impaired by Furin Inhibitors or a Subset of Monoclonal Antibodies.SARS-CoV-2 刺突蛋白能够独立于其受体 ACE2 诱导细胞-细胞融合，而这种活性可以被弗林蛋白酶抑制剂或一组单克隆抗体所抑制。
Viruses. 2023 Jul 4;15(7):1500. doi: 10.3390/v15071500.
10
Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines.基于 SARS-CoV-2 受体结合域的 COVID-19 疫苗的进展。
Expert Rev Vaccines. 2023 Jan-Dec;22(1):422-439. doi: 10.1080/14760584.2023.2211153.
Zotero 插件